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Abstract: Recent outbreaks of Rift Valley fever in ruminant livestock, characterized by mass abortion
and high mortality rates in neonates, have raised international interest in improving vaccine control
strategies. Previously, we developed a reliable challenge model for sheep that improves the
evaluation of existing and novel vaccines in sheep. This sheep model demonstrated differences
in the pathogenesis of Rift Valley fever virus (RVFV) infection between two genetically-distinct
wild-type strains of the virus, Saudi Arabia 2001 (SA01) and Kenya 2006 (Ken06). Here, we evaluated
the pathogenicity of these two RVFV strains in mixed breed beef calves. There was a transient increase
in rectal temperatures with both virus strains, but this clinical sign was less consistent than previously
reported with sheep. Three of the five Ken06-infected animals had an early-onset viremia, one day
post-infection (dpi), with viremia lasting at least three days. The same number of SA01-infected
animals developed viremia at 2 dpi, but it only persisted through 3 dpi in one animal. The average
virus titer for the SA01-infected calves was 1.6 logs less than for the Ken06-infected calves. Calves,
inoculated with either strain, seroconverted by 5 dpi and showed time-dependent increases in their
virus-neutralizing antibody titers. Consistent with the results obtained in the previous sheep study,
elevated liver enzyme levels, more severe liver pathology and higher virus titers occurred with
the Ken06 strain as compared to the SA01 strain. These results demonstrate the establishment of a
virulent challenge model for vaccine evaluation in calves.
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1. Introduction
The mosquito-borne Rift Valley fever virus (RVFV) is a zoonotic pathogen within the genus
Phlebovirus family Bunyaviridae. The virus has a tripartite, single-stranded negative-sense RNA
genome. The large segment (L) encodes the RNA-dependent RNA polymerase. The medium
segment (M) encodes two major envelope glycoproteins, Gn and Gc, and a non-structural protein,
NSm. The S-segment utilizes an ambisense strategy to encode the nucleocapsid protein and the
non-structural protein, NSs, which has been shown to be an interferon antagonist [1]. Although
large outbreaks have predominantly occurred in Sub-Saharan Africa, outbreaks outside of the African
continent, in the Arabian Peninsula, have raised concerns about the potential spread of the virus
to Europe and the Americas [2,3]. These concerns are warranted given that North America has
large, economically-important populations of susceptible animals and indigenous vector populations,
experimentally shown to be competent for virus infection and transmission [4–6]. Typically, outbreaks
of disease are characterized by abortion storms and high rates of mortality in young sheep, goats
and cattle [7,8]. Livestock are considered to be the amplifying and/or reservoir hosts for human
infections. Thus, outbreaks in livestock lead to human infections, resulting in acute febrile illness that
in some cases can progress to more severe disease, including retinal vasculitis, resulting in blindness,
encephalitis and fatal hepatitis with hemorrhagic fever [9]. Although reported human case fatality
rates are generally low, higher fatality rates (20%–40%) have been noted [10,11].
RVFV is a Category A pathogen [12], and the potential for RVFV as a bioterrorism agent is
widely recognized [13]. Therefore, the intentional or unintentional introduction of RVFV into the
U.S. is both an agricultural and public health concern and requires a “One Health” approach. One
primary control method is through livestock vaccination [14,15]. Killed or live attenuated vaccines
are currently used in endemic countries. Historically, the commonly-used veterinary vaccine is an
attenuated vaccine developed in 1949 known as the Smithburn strain [16]. A more recently introduced
attenuated vaccine is Clone 13, which has a deletion in the NSs interferon antagonist gene and has been
experimentally proven to be safe and efficacious [17,18]. Another attenuated vaccine that is considered
to be safe is MP12 [19–21], which is conditionally licensed for use in the U.S. [22]. MP12 has also been
evaluated for potential human use [23,24]. There are concerns with the use of attenuated vaccines
due to potential teratogenicity [25] and potential reversion to virulence or reassortment with RVFV
field strains. A number of novel vaccine approaches are in development [1], the most recent being an
adenovirus-vectored vaccine [26]. With multiple inactivated, live attenuated and other new generation
potential vaccines, there is a critical need for consistent, reliable vaccine efficacy animal models based
on the target species (i.e., sheep, goats or cattle). Animal models are available [27], and because
abortion is a hallmark of RVFV of livestock, a common model is the pregnant ewe [28]. However, the
pregnancy synchronization of ewes and the scheduling of limited high biosecurity animal space makes
this model logistically difficult. Another model that has proven useful is vaccine-age (~4-month-old)
sheep and goats [29]. This study involved different breeds of sheep (Suffolk cross, Rideau Arcott cross,
Ile-de-France cross with Rideau Arcott) and a human-derived virus, the Egyptian 1977 virus strain
ZH501. Although no severe pathology was reported in the ZH501-infected sheep, viremia and febrile
response allowed for the evaluation of vaccine efficacy [30].
We recently adopted this model to evaluate the pathogenicity of two genetically-distinct RVFV
strains in sheep [31]. The first strain, Saudi Arabia 2001 (SA01), was originally isolated from Aedes
vexans arabiensis during the 2000–2001 outbreak in the Kingdom of Saudi Arabia [32]. This outbreak
had higher human case fatality rates than previously noted (13.9%–33.9%) [33]. The second strain,
Kenya 2006 (Ken06), was isolated from Aedes ochraceus from Kenya in 2006 [34]. While Ken06 was
found to be closely related to viruses isolated in 1991 in Madagascar and in 1997 in Kenya [32],
it is genetically distinct from these viruses [31]. Our sheep challenge model for SA01 and Ken06
RVFV demonstrated differences in viremia, microscopic and macroscopic pathological changes and
aberrations in hematology and liver enzyme chemistry values. The aim of the present study was to
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further compare and confirm these virulence differences by evaluating SA01 and Ken06 infections in
another important target species, cattle.
2. Materials and Methods
2.1. Virus Strains and Cell Culture
The RVFV Saudi Arabia 2000–2001 (SA01) [34] and Kenya 2006–2007 (Ken06) isolates [32] were
provided by Barry Miller, Centers for Disease Control, Fort Collins, CO, through Richard Bowen,
Colorado State University. The two virus strains were passaged once in a C6/36 Aedes albopictus cell
line (ATCC, Manassas, VA, USA) at 30 ˝C with MEM culture medium (Life Technologies, Grand Island,
NY, USA) supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich, St. Louis, MO, USA)
and 1ˆ antibiotic-antimycotics (Penicillin/Streptomycin/Amphotericin B (PSF); Gibco, Watham, MA,
USA). Plaque assays were performed using the Vero MARU (Middle America Research Unit, Panama)
cell line grown in M199E culture medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with
10% FBS and 1ˆ PSF and maintained in a 37 ˝C, 5% CO2 incubator.
2.2. Animals and Experimental Design
Twelve healthy Hereford cross or Angus cross cattle, 4–5 months old, were obtained from private
breeders in Kansas, USA. The animals were acclimated for one week at the Large Animal Research
Center (Kansas State University (KSU), Manhattan, KS, USA) prior to relocation to a Biosafety Level-3
Agriculture (BSL-3Ag) facility at the KSU Biosecurity Research Institute for the virus inoculation
experiment. In the BSL-3Ag facility, the animals were divided into two experimental groups of five each.
Two additional animals were included as mock-inoculated controls. Cattle in each experimental group
were inoculated subcutaneously with 2 mL of 1 ˆ 106 plaque-forming units (pfu)/mL of the Ken06
or SA01 strain. After RVFV exposure, all animals were monitored daily for temperature changes and
clinical signs. Nasal swabs for virological analysis and blood samples for virological, immunological,
and blood chemistry analyses were collected daily from Days 0–10 and additionally at 14 and 21 days
post-infection (dpi). One animal per experimental infection group was euthanized and necropsied at 3,
4, 5, 10 and 21 dpi. Animals were randomly pre-selected for necropsy; however, severe clinical illness
required one animal to be substituted earlier in the schedule. The two mock-inoculated control cattle
were necropsied at 20 dpi in order to allow for complete and thorough necropsies on all animals under
BSL-3Ag conditions. Tissues were collected for viral titer determinations and histopathology. The
research was performed under an Institutional Animal Care and Use Committee-approved protocol
of KSU in compliance with the Animal Welfare Act and other regulations relating to animals and
experiments involving animals.
2.3. Virus Isolation and Plaque Titration
Tissue samples of brain, kidney, liver and spleen were collected at necropsy and frozen at ´80 ˝C.
Approximately 10 mg of tissue were added to 1 mL M199E supplemented with 10% FBS and
1ˆ PSF and homogenized by high-speed shaking dissociation with steel beads using the TissueLyser
instrument (QIAGEN Inc.; Valencia, CA, USA). Virus stocks, cattle sera, nasal swabs and homogenized
tissue samples were titered by standard plaque assay on Vero MARU cells, as previously described [35].
Briefly, confluent cell monolayers were inoculated with ten-fold serial diluted samples in M199E
and incubated for 1 h. Following adsorption, the inocula were replaced with a 1:1 mixture of 2%
carboxymethyl cellulose (Sigma-Aldrich, St. Louis, MO, USA) in 2ˆM199E (2% FBS and 2ˆ PSF) and
returned to the incubator. After five days, cells were fixed and stained with crystal violet fixative (25%
formaldehyde, 10% ethanol, 5% acetic acid, 1% crystal violet).
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2.4. Viral RNA Extraction and Real-Time RT-PCR
Total RNA from serum, nasal swabs or homogenized tissue samples was extracted using TRIzol-LS
reagent (Life Technologies, Grand Island, NY, USA) and the magnetic-bead capture MagMAX-96 total
RNA Isolation kit (Life Technologies). Briefly, 100 µL of aqueous phase were added to 90 µL of
isopropanol and 10 µL bead mix (Beckman Coulter, Danvers, MA, USA). Total sample RNA was
washed four times with wash buffer (150 µL) and then eluted in 30 µL of elution buffer. A quadruplex
real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay was used to detect each of
the three RVFV RNA genome segments and an external RNA control [36].
2.4.1. RNA Copy Number Determination
In vitro transcribed RNA (IVT RNA) was generated using the T7 transcription kit (MEGAscript,
ThermoFisher) from a PCR-generated amplicon derived from a DNA plasmid (pBluescript III)
using cDNA SuperMix (Quanta Biosciences) and T7 promoter and terminator primers (Integrated
Technologies). The RVFV L plasmid (provided by Hana Weingartl, National Centre for Foreign
Animal Diseases, Canadian Food Inspection Agency, Manitoba, Canada) contains 3482 base pairs
of the L segment of RVFV (nucleotides 1–3482 of the ZH501 RVFV strain). IVT RNA was DNAse
treated 3ˆ, column purified (MEGAclear, ThermoFisher) and quantitated with spectrophotometry.
The copy number was calculated using an online calculator [37]. Ten-fold serial dilutions of IVT
stock RNA (104–10´1 copies) were utilized to generate a six-point standard curve using six PCR well
replicates per dilution using quantitative RVFV real-time RT-PCR [36]. Copy numbers for samples were
mathematically determined using the PCR-determined mean Ct for the L segment (three PCR well
replicates) and the slope and intercept of the L segment IVT RNA standard curve. Data are reported as
PCR-determined copy number per reaction. Calculated copy numbers less than 15 (equivalent to Ct
greater than 35) are considered past the limits of detection for this assay, are classified as equivocal
and, thus, are not reported as true positives.
2.5. RVFV Serology
2.5.1. Anti-RVFV IgG Antibody Response
The serum was inactivated prior to serological testing by adjusting to 0.25% Tween and incubating
at 60 ˝C for 2 h. Each sample was safety tested by 3 blind passes in cell culture. Only samples
that demonstrated no cytopathic effect on the third passage were removed for serology. Anti-RVFV
antibody response was measured by an anti-RVFV total IgG indirect enzyme linked immunosorbent
assay (ELISA) using recombinant baculovirus-expressed RVFV Gn and N proteins as diagnostic
antigens. Briefly, each plate was coated overnight at 4 ˝C with approximately 150 ng of each purified
recombinant protein/antigen, and the ELISA was performed as previously described [38]. The cut-off
point for the specific ELISAs was determined by the addition of three standard deviations to the
corresponding mean OD value of the pre-vaccination for all of the animals and the control serum.
Mean OD values equal to or greater than the cut-off value were considered positive.
2.5.2. Plaque Reduction Neutralization Test
To assess the anti-RVFV neutralizing antibody response to RVFV inoculation, a plaque reduction
neutralization test was performed as previously described [39]. Briefly, the stock of MP12 RVFV was
diluted to 50 pfu in 250 µL of 1ˆMEM containing 4% bovine serum albumin (BSA; Sigma-Aldrich).
Separately, aliquots of serum from each animal were serially diluted from 1:10–1:1280 in 1ˆ MEM
containing 2% BSA and 1% penicillin-streptomycin (Gibco). Diluted serum (250 µL) was mixed with
an equal volume of diluted MP12 virus and incubated at 37 ˝C for 1 h. Thereafter, each mixture of
serum plus RVFV was used to infect confluent monolayers of Vero E6 cells (ATCC, Manassas, VA,
USA) in 12-well plates. After 1 h of adsorption at 37 ˝C and 5% CO2, the mixture was removed, and
1.5 mL of nutrient agarose overlay (1ˆ MEM, 4% FBS and 0.9% SeaPlaque agar (Lonza Rockland
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Inc., Rockland, ME, USA)) were added to the monolayers. After 4 days of incubation, the cells
were fixed with 10% neutral buffered formalin for 3 h prior to removal of the agarose overlay. The
monolayer was stained with 0.5% crystal violet in PBS, and plaques were enumerated. The calculated
plaque reduction neutralization test (PRNT80) corresponded to the reciprocal titer of the highest serum
dilution, which reduced the number of plaques by 80% or more relative to the virus control. As the
positive neutralizing serum control, a 1:40 dilution of Day 28 neutralizing serum (titer >1280) obtained
from sheep previously immunized with the RVFV glycoprotein subunit vaccine was used [39].
2.6. Blood Chemistry Analyses
An aliquot of serum was frozen immediately upon processing for later comprehensive large
animal diagnostic panel (ALB, ALP, BUN, CA, CK, GGT, GLOB, MG, PHOS and TP) analyses with a
Vetscan VS2 instrument (Abaxis, Union City, CA, USA) according to the manufacturer’s instructions.
Vendor-provided normal ranges for cattle were used as reference values.
2.7. Liver Pathology
Cattle liver samples were collected at necropsy and placed in 10% neutral buffered formalin for at
least 7 days. Liver tissue was trimmed, processed and paraffin-embedded. All histochemical stains and
immunohistochemistry were done on 4-µm sections placed on positively-charged slides. Hematoxylin
and eosin (H&E)-stained tissues were reviewed by a veterinary pathologist in a blinded fashion and the
liver pathology scored per slide (2–3 slides, minimum 3 tissues sections per animal) for lesion severity
on a semi-quantitative scale from 0–4, where 0 signified no lesions and 1–4 progressively more severe
pathology with a greater degree of liver parenchyma involvement (Table 1). Immunohistochemistry
(IHC) for RVFV antigen using the polyclonal rabbit anti-RVFV nucleocapsid protein antibody [40]
and an avidin-biotinylated peroxidase complex (ABC) detection technique was conducted on all
liver sections as described [31], with the addition of a chromogen-enhancing step. Briefly, slides
were deparaffinized and rehydrated, the antigen retrieved using a vegetable steamer technique in
pH 6.0 citrate buffer with detergents (DAKO, Carpinteria, CA, USA) for 20 min, blocked with 3%
hydrogen peroxide for 10 min, serum blocked as per the kit, incubated overnight at 4 ˝C with a
1:1000 dilution of primary antibody, secondary antibody, and ABC reagent was applied as per kit,
with 3,3’-Diaminobenzidine (DAB) followed by DAB enhancing solution applied as per the vendor
instructions (Vector Labs), counterstained with hematoxylin and mounted in Permount (Electron
Microscopy Systems, Hatfield, PA, USA). Throughout, the following controls were employed: reagent
control slides, with and without equivalent concentrations of primary antibody matched animal serum,
and uninfected control cattle liver. Additionally, a Hall’s histochemical stain for bilirubin was run
on select liver sections. All gross tissue images were captured with a Canon G12 camera (Cannon,
USA Inc., Melville, NY, USA), and microscopic images were captured with a DP25 camera (Olympus,
Tokyo, Japan) on a BX46 light microscope (Olympus) using CellSens Standard Version 1.12 (Olympus).
All microscopic images were further color calibrated using ChromaCal software ver 2.5 (Datacolor
Inc., Lawrenceville, NJ, USA) as per the manufacturer’s instructions and published recommendations
(Linden, Sedgewick and Ericson, 2015); the figure panels were composed in Adobe Photoshop and
InDesign CC (Adobe, San Jose, CA, USA).
Table 1. Liver histopathology score descriptions.
Histopathology Score Description
0 Multifocal, peri-portal, mild lymphoplasmacytic (lymphocytesand plasma cells) inflammation (background lesion)
1
Multifocal, mid-zonal to central foci of lymphohistiocytic
(lymphocytes and macrophages) inflammation with lesser
numbers of plasma cells and occasional single hepatocyte
necrosis accompanied by low numbers of neutrophils




Multifocal, up to 1-mm areas of mid-zonal to central
lymphohistiocytic inflammation involving up to 5% of the
examined parenchyma; in the foci with central necrosis, the
inflammation shifts to predominantly neutrophils; less than 5%
of examined parenchyma involved
3
As prior, but including scattered necrotic foci that have >1
mm-diameter areas and involving up to 20% of the hepatic tissue
reviewed; scattered hepatocyte apoptosis is additionally present
4
Greater than 20% of the hepatic parenchyma involved with
lesions, as described previously; additionally, there is prominent
multifocal hemorrhage
2.8. Statistical Analysis
Differences in values of key experimental parameters were analyzed statistically. The values were
analyzed using the t-test for independent samples. Mean and standard deviations were calculated
for animals available per days post-infection (dpi). The small number of animals used due to space
constraints (BSL-3Ag) reduced the value of statistical analysis.
3. Results
3.1. Rectal Temperatures
Rectal temperatures of calves inoculated with SA01 or Ken06 were monitored from 0–10, 14 and
21 dpi (Table 2). Two out of the five animals inoculated with SA01 had a fever (>40 ˝C) at 2 dpi, while
the others were normal throughout the study. At 2 dpi or later, four out of five animals inoculated
with Ken06 had a fever for at least one day, and one had a consistent fever for three days (Table 2).
Rectal temperatures were within normal limits for all of the animals remaining past 7 dpi.
Table 2. Kinetics of the rectal temperature (˝C) of calves infected with Rift Valley fever virus
(RVFV) strains, Saudi Arabia 2001 (SA01) and Kenya 2006 (Ken06) (red indicates above normal for
cattle, >40 ˝C).
Days Post-Infection
Strain No. 0 1 2 3 4 5 6 7
SA01
33 39.4 38.7 41.3 38.8 39.0 38.6 39.8 38.3
34 39.2 38.8 39.6 38.9 38.7 38.5
37 38.9 38.9 38.8 39.0 38.7
39 39.1 38.4 40.9 39.8 39.2 38.8 38.9 38.6
43 39.8 38.9 39.5
Ken06
36 40.4 39.4 39.3 38.3 38.7 38.8
38 38.9 38.9 41.5 41.6 41.1
40 39.0 38.8 38.8 38.9 38.8 40.8 39.3 38.5
41 39.2 39.1 40.8 39.8
44 39.4 39.7 40.7 39.5 39.1 38.3 38.3 38.5
Control
35 39.1 39.4 38.8 38.6 38.4 38.7 38.3 38.3
42 39.0 40.3 38.5 38.9 39.3 38.6 38.8 38.5
3.2. RT-RCR and Viremia
Viremia was determined in the cattle sera by both real-time RT-PCR and virus titration up
to 21 dpi. Virus was detectable in the serum starting at 1 dpi by both real-time RT-PCR (Figure 1A–C)
and the plaque assay (Figure 1D) for the Ken06 group. Viral RNA and virus were detected from the
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sera of Animal #38 of the Ken06 group at 1 dpi. By 2 dpi, four of five in the SA01 group and three of
five in the Ken06 group were positive by real-time RT-PCR, and also, three of five in both groups were
viremic (Figure 1A–D). All infected animals were at least weakly positive by real-time RT-PCR (cycle
threshold (Ct) ď37; the standard cut-off threshold is 35), but only three of five animals per group had
detectable viremia by virus titration. There was individual animal variation in the detection of viral
RNA and virus isolation (Figure 2). The detection of virus occurred just prior to the appearance of
fever, at 1 dpi for the Ken06 group, but there was viral RNA and viremia in the SA01 group in the
absence of fever. One calf in the Ken06 group had a late fever at 5 dpi and was never positive for viral
RNA using the quantitative RT-PCR test criteria Ct ď 35 for two of three RVFV gene segments or virus
isolation. This animal did have some questionable positive quantitative RT-PCR results (Ct = 35–39)
from 5–7 dpi and did have a viral RNA positive nasal swab at 5 dpi.
Peak viremia determined by the plaque assay occurred at 2 and 3 dpi (Figure 1D). Cattle infected
with the SA01 strain were all negative by both real-time RT-PCR (Figure 1A–C) and the plaque assay
by 4 dpi (Figure 1D). Cattle inoculated with the Ken06 strain were negative by real-time RT-PCR
(Figure 1A–C) by 5 dpi, but some weakly positive Ct values above the standard threshold cut-off of 35
were detected out to 7 dpi. No virus plaques were detected by Day 5 dpi for Ken06 (Figure 1D). One
animal in the Ken06 group was viremic from 1–4 dpi and died immediately prior to necropsy at 4 dpi.
This animal had a peak viremia of 3.4 ˆ 108 pfu/mL at 2 dpi with real-time RT-PCR Ct values of 14–19
depending on the viral segment used for detection. Control co-housed cattle sera remained negative
by RT-PCR and virus titration throughout the study.
Viruses 2016, 8, 145 7 of 15 
 
35 wer  d tected out to 7 dpi. No virus plaques wer  det cted by Day 5 dpi for Ken06 (Figure 1D). One 
animal in the Ken06 group was viremic from 1–4 dpi and died immediately prior to necropsy at 4 
dpi. This anim l h d a p ak viremia of 3.4 × 108 pfu/mL at 2 dpi with r al-time RT-PCR Ct values of 
14–19 depe ding on the viral segment used f r detecti n. Control co-hous d cattle s ra r main d 
negative by RT-PCR and virus titrati n throughout the study. 
 
Figure 1. Kinetics of viral RNA and virus titers for calves infected with RVFV strains, SA01 (blue) and 
Ken06 (gray). The mean with the standard deviation of change in Ct values; (40-Ct)/40 (A) RVFV L 
RNA segment (dashed line indicates standard Ct = 35 cut-off or 0.13 change in Ct), (B) RVFV M RNA 
segment and (C) RVFV S RNA segment from calf serum are shown; (D) viral titers in pfu/mL. To be 
considered positive by the multiplex real-time RT-PCR, the Ct value for at least two of the three RVFV 
genome segments must be less than or equal to 35 [36]. 
 
Figure 2. Viral replication dynamics in individual calf serum as determined by molecular and 
traditional virological methods. (A) Quantitative real-time RT-PCR-determined RVFV L segment 
copy number per reaction calculated from the mean Ct for the RVFV L segment from Day 0–Day 5 
post-infection; (B) RVF virus titer determined from the plaque assay reported as pfu/mL of serum. 
Figure 1. Kinetics of viral RNA and virus titers for calves infected with RVFV strains, SA01 (blue) and
Ken06 (gray). The mean with the standard deviation of change in Ct values; (40-Ct)/40 (A) RVFV L
RNA segment (dashed line indicates standard Ct = 35 cut-off or 0.13 change in Ct), (B) RVFV M RNA
segment and (C) RVFV S RNA segment from calf serum are shown; (D) viral titers in pfu/mL. To be
considered positive by the multiplex real-time RT-PCR, the Ct value for at least two of the three RVFV
genome segments must be less than or equal to 35 [36].
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Figure 2. Viral replication dynamics in individual calf serum as determined by molecular and
traditional virological methods. (A) Quantitative real-time RT-PCR-determined RVFV L segment
copy number per reaction calculated from the mean Ct for the RVFV L segment from Day 0–Day 5
post-infection; (B) RVF virus titer determined from the plaque assay reported as pfu/mL of serum.
PCR Ct equal to or less than 35 equates to greater than 27 copies, which is considered positive and
within the quantitative range for quantitative RT-PCR. The X-axis includes calf numbers and group
designations; CTL = mock controls, SA01 = infected with RVFV Saudi Arabia 2000–2001; K06 is Ken06 =
infected with RVFV Kenya 2006–2007. Calves 43 and 41 were necropsied at dpi 3 and, thus, are not
included in the datasets for dpi 4 or 5. Calves 37 and 38 were necropsied on dpi 4 and, thus, are not
included in datasets for dpi 5.
3.3. Viral Load or Titers in Tissues
Brain, kidney, liver and spleen samples collected at necropsy were also tested for virus presence
(Table 3). The Ken06 group Animals #41 at 3 dpi and #38 at 4 dpi had viral RNA-positive brain tissue
(average of L, M and S Ct = 34 and 31, respectively). Viral RNA was also found in the kidneys of the
Ken06 group cattle, #41 at 3 dpi (average of L, M and S Ct = 28) and #38 at 4 dpi (average of L, M and S
Ct = 23), as well as the SA01 group Animal #34 at 5 dpi (average of L, M and S Ct = 26). Virus was
isolated from the kidneys of #38 (1.4 ˆ 105 pfu/mL) and #34 (1.5x102 pfu/mL). Liver samples from
both groups were positive for viral RNA from 3–4 dpi and at 5 dpi for the SA01 group (Ct = 18–30).
At 5 dpi, the SA01 animal’s liver tissue was positive for viral RNA (Ct = 29), but the Ken06 was
inconclusive (Ct = 38). Virus was isolated from the liver of both groups at 3 dpi and for a Ken06 animal
at 4 dpi (Table 3). The spleen results reflected the liver results for viral RNA detection with Ct values
from 21–33 from 3–5 dpi. Virus was isolated only from the spleens of Ken06 animals at 3 and 4 dpi
with titers of 1.2 ˆ 103 pfu/mL and 2.9 ˆ 105 pfu/mL, respectively. The spleens were positive for
viral RNA at 10 dpi from both groups (SA01, Ct = 33; Ken06, Ct = 35). The spleens from both groups
were weakly positive at 21 dpi (Ken06, Ct = 36) and inconclusive (SA01, Ct = 38). Nasal swabs from
both groups were sporadically positive for viral RNA from 3–6 dpi (total of nine positive samples;
Ct = 26–34; data not shown). One swab from Animal #38 was found virus positive (32 pfu/mL). The
greatest number of positive nasal swabs was at 3 dpi with three out of five for the SA01 group (average
of L, M and S Ct = 32) and two out of five for the Ken06 group (average of L, M and S Ct = 34).
Virus was isolated from the nasal swab of only the Ken06 group Calf #38 that also had the highest
serum virus titer of 3.5 ˆ 108 pfu/mL, whereas the highest titer of the SA01 group found in Calf #34
was 2.2 ˆ 103 pfu/mL.
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Table 3. Presence of RVFV RNA and virus in tissues at days post-infection.
Days Post-Infection
3 4 5 10 20
Ct Titer Ct Titer Ct Titer Ct Titer Ct Titer
SA01 Brain ND - ND - ND - ND - ND -
Kidney ND - 37 - 26 1.5 ˆ 102 ND - ND -
Liver 30 4.0 ˆ 10˝ 30 - 29 - 37 - ND -
Spleen 31 - 33 - 32 - 33 - 38 -
Ken06 Brain 34 - 31 - 38 - ND - ND -
Kidney 28 - 23 1.4 ˆ 105 ND - ND - ND -
Liver 20 2.1 ˆ 105 18 3.9 ˆ 106 38 - ND - ND -
Spleen 24 1.2 ˆ 103 22 2.9 ˆ 105 ND - 35 - 36 -
Titer: pfu/mL from 10 mg homogenate in 1 mL of media; Ct = cycle threshold mean of S, L, M, real-time
RT-PCR; ND = not detected or Ct of 40; - = no plaque formation.
3.4. Serological Responses
Calves showed the first indication of seroconversion at 6 dpi with OD values above the cut-off
points for reactivity to N and 10–14 dpi for reactivity to Gn (Figure 3A, B). Serum samples from 1–3 dpi
were not included in the analysis because our standard inactivation procedure failed to fully inactivate
the virus due to the presence of high virus titers in some of the sera. Neutralizing antibody responses
were detected in remaining animals at 5 dpi and increased until peaking at 10–14 dpi (Table 4) consistent
with the ELISA data and indicating serological conversion in response to the experimental RVFV
inoculations. None of the co-housed control cattle seroconverted.Viruses 2016, 8, 145 9 of 15 
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urine observed ante-mortem. In all animals necropsied at 10 dpi and later, gross changes in hepatic 
parenchyma were no longer evident. 
Similar to the gross lesion results, we did not find RVFV strain-dependent patterns between the 
two groups in terms of hepatic histopathology changes. RVFV-infected cattle had severe hepatic 
lesions at 3–5 dpi, averaging no less than 2.5 (scale 0–4) for their hepatic histopathology score  
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necrosis disseminated throughout their hepatic parenchyma accompanied by predominantly 
lymphohistiocytic, inflammation and increased numbers of degenerate and viable neutrophils in 
Figure 3. Development of the antibody response of individual calves infected with RVF str i , SA01
(blue) and Ken06 (gray). Specific indire t ELISA shows t e kinetics of total IgG antibody responses
in sh e inoculated with wild-type RVFV strains, SA01 and Ken06: (A) RVFV N-ELISA; (B) RVFV
Gn-ELISA. The dashed line indicates the calculated cut-off values (N-ELISA = 0.27; Gn-ELISA = 0.33).
Table 4. Reciprocal plaque reduction neutralization test (PRNT80) titers in calves infected with RVFV
strains, SA01 and Ken06.
Days Post Infection
Strain No. 0 4 5 6 7 10 14 21
SA01 33 - - 10 40 160 640 1280
39 - - 10 160 320 >1280
34 - - -
37 - -
43 -
Mean 10 100 240 960
Ken06 40 - - 40 40 80 1280 640 >1280
44 - - 40 80 320 1280
36 - - -
38 - ND
41 -
Mean 40 60 200 1280
- = negative; ND = not determined.
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3.5. Pathology
In general, gross pathology observations at 3–5 dpi revealed no consistent pattern of difference
between the SA01 and Ken06 virus strains groups; all had 1–3-mm multifocal tan foci (necrotic
foci) disseminated throughout their hepatic parenchyma (Figure 4A). However, gross findings for
Animal #38 (4 dpi Ken06 inoculated) were more severe. This animal had multifocal to coalescing
hepatic necrosis accompanied by marked, multifocal hemorrhage disseminated throughout its hepatic
parenchyma (Figure 4B). Additionally, #38 had clinical signs and lesions suggestive of disseminated
intravascular coagulation, including hemorrhage and edema in multiple viscera, many edematous
and congested lymph nodes throughout its body, renal pelvic hemorrhage, splenic ecchymoses,
marked and diffuse pulmonary congestion, multifocal endocardial hemorrhage and red urine observed
ante-mortem. In all animals necropsied at 10 dpi and later, gross changes in hepatic parenchyma were
no longer evident.
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Figure 4. Gross pat o ogy of acute post-infect on, time-point livers from virus-inoculated cattle.
(A) This liver from SA01-inoculated, 3 dpi, Animal #43 shows the typical acute time-point hepatic
pathology seen in the 3–5 dpi nimals regardles o virus inoculum. Disseminated throughout
the parenchyma are myriads of 1–2-mm tan foci (white arrows), necrosis. (B) This liver from
severely affected Ken06-inoculated, 4 dpi, Animal #38 is diffusely pale. Disseminated throughout
the parenchyma are multifocal to coalescing foci of necrosis (white arrows) and hemorrhage (white
arrowheads). Inset 1 is a capsular liver view similar to the inset in (A), while Inset 2 shows a
cross-section of hepatic parenchyma.
Similar to the gross lesion results, we did not find RVFV strain-dependent patterns between
the two groups in terms of hepatic histopathology changes. RVFV-infected cattle had severe hepatic
lesions at 3–5 dpi, averaging no less than 2.5 (scale 0–4) for their hepatic histopathology score (Table 5
and Figure 5). All of these animals had multifocal mid-zonal to central hepatocellular necrosis
disseminated throughout their hepatic parenchyma accompanied by predominantly lymphohistiocytic,
inflammation and increased numbers of degenerate and viable neutrophils in larger necrotic foci.
The lesions tapered off by 10 dpi (score ď2) and by 21 dpi were characterized by occasional foci of
inflammation, predominantly aggregates of lymphocytes and macrophages.
In contrast, while the sample size per time-point prevented us from appreciating histopathologic
differences attributable to virus strai , we saw a consistent difference in immunohistochemical (IHC)
labeling for RVFV nucleoprotein antigen in the hepatic lesions at 3 and 4 dpi SA01 cattle. As seen
in our prior challenge model work in sheep [31], SA01 hepatic lesions contained notably less viral
antigen signal than hepatic lesions in ime-point matched K 06 cattle. Figure 5F shows a typical
Ken06 hepatic lesion IHC signal (Figure 5F), whereas Figure 5I shows a stronger than average labeling
of a hepatic lesion in an SA01 animal (Figure 5I). Finally, all examined cattle livers, regardless of
inoculum type, had mild, peri-portal lymphoplasmacytic inflammation, interpreted as background
inflammation unrelated to the study. Additionally, mock-inoculated, co-housed Animal #42, unlike
its mock-inoculated peer, Animal #35, had low numbers of scattered foci of mixed inflammation in
central and mid-zonal areas. These foci were negative for RVFV antigen and may be attributable to an
unrelated etiology.
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Table 5. Liver histopathology and immunohistochemistry for RVFV antigen.
Strain Calf No. Days PI H Score IHC PCR Titer
SA01
43 3 3 + + 4.0 ˆ 10˝
37 4 2.5 + + -
34 5 3 + + -
39 10 2 - - -
33 21 1 - - -
Ken06
41 3 3 + + 2.1 ˆ 105
38 4 4 + + 3.9 ˆ 106
36 5 1 + * - -
44 10 2 - - -
40 21 1 - - -
Mock
35 20 0 - - -
42 20 0 - - -
H Score is the average hepatic histopathology score on a scale from 0, no lesions, to 4, severe lesions (Table 1),
for 3–5 reviewed sections of liver per animal. IHC is the anti-RVFV immunohistochemistry (IHC) result on liver
sections; a positive “+” is given when at least one section of liver was positive for viral antigen. Key: + = positive
for viral antigen by IHC; - = negative for viral antigen by IHC. PCR is the quantitative RT-PCR result for liver
tissue. * No viral antigen-positive lesions; a positive cytoplasmic signal is present in low numbers of circulating
Kupffer cells (macrophages). The titer is pfu/mL of tissue homogenate from 10 mg of tissue in 1 mL of media
(- = no plaques).
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transferase (AST), the hepatic leakage enzyme consistent with acute liver damage, was elevated 
above normal range (66–211 U/L) in two of the Ken06 group animals, #38 (2–4 dpi; 279, 1959, 1742 U/L, 
respectively) and #41 (3 dpi; 452 U/L). Using ALP values normalized to 0 dpi values for individual 
animals, the only animal with a significant elevation in its ALP was Ken06 Animal #38 starting at 3 dpi 
(0–4 dpi; 149, 151, 155, 451, 476 U/L, respectively). Animal #38 was also the only one with an elevation 
Figure 5. Acute ti e-point liver histopathology and viral antigen im unohistochemistry. (A) Shown
is a low agn fi ation he toxylin and e si (H&E) s ain of th normal l ver histology seen in
mock-inoculated Animal #42; the black broken line box outlines the area magnified in (B); (C) viral
antigen immunohistochemistry is negative for RVFV antigen; (D) the depicted Ken06, 3 dpi, Animal
#41 liver H&E is representative of the acute time-point histopathology seen in animals inoculated by
this virus; the black stars mark necrotic foci; a portio of one focus is magnified in (E); (F) shown is
the same necrotic focus, which is strongly positive for RVFV antigen in hepatocytes, macrophages
and cellular debris; black arrowheads indicate cytoplasmic positive labeling; (G) the depicted SA01,
3 dpi, Animal #43 liver H&E is typical of acute time-point liver histopathology for this virus strain;
the black star denotes a single large necrotic focus further magnified in (H); acute time-point SA01
liver foci labeled sporadically and less strongly for RVFV antigen when compared to Ken06 foci; (I) a
stronger than average viral antigen labeling for this larger than average necrotic focus in Animal #43;
black arrowheads denote RVFV antigen labeling. Column 1 images are 100ˆmagnification. The bar
is 20 µm. Columns 2 and 3 images are 400ˆmagnification. Bars are 50 µm.
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3.6. Blood Chemistry
Blood chemistries were run on all sera available from 0–7 dpi. Of the 14 parameters assessed,
significant elevations were seen in multiple hepatic enzymes, BUN, an indicator of renal damage, as
well as creatinine kinase (CK), an indicator of skeletal muscle damage (data not shown). These changes
were all found in RVFV-infected animals with the exception of CK. Aspartate amino transferase (AST),
the hepatic leakage enzyme consistent with acute liver damage, was elevated above normal range
(66–211 U/L) in two of the Ken06 group animals, #38 (2–4 dpi; 279, 1959, 1742 U/L, respectively)
and #41 (3 dpi; 452 U/L). Using ALP values normalized to 0 dpi values for individual animals, the
only animal with a significant elevation in its ALP was Ken06 Animal #38 starting at 3 dpi (0–4 dpi;
149, 151, 155, 451, 476 U/L, respectively). Animal #38 was also the only one with an elevation in
gamma-glutamyl transferase (GGT) at 3–4 dpi (90 and 100 U/L, respectively). This animal had the most
severe hepatic histopathology as documented above, but no evidence of cholestasis (associated with
high ALP and GGT values) was seen during the histopathology analysis. An additional check with
a Hall’s bilirubin stain on multiple liver sections confirmed an absence of bilirubin in bile canaliculi,
a hallmark of cholestasis. Animal #38 also had high BUN levels at 4 dpi (32 mg/dL), immediately
prior to death. Finally, Animal #38 and SA01 group Animal #37 both had a single elevated CK value
accompanied by a high normal value on a consecutive day indicating muscle damage, #37 (3–4 dpi; 797
and 504 U/L, respectively) and #38 (3–4 dpi; 585 and 834, respectively). Interestingly, while Animal #38
had severe clinical signs, Animal #37 did not show obvious clinical signs; it did have significant hepatic
pathology (see the pathology section). One of the mock-inoculated, co-housed cattle had a single
elevated CK value (1175 U/L), most likely due to difficult restraining procedures during sampling.
4. Discussion
The development of reliable challenge models for arboviral disease is often challenging because
needle inoculation does not mimic natural infection via insect vectors. There has been significant
effort made in the development of vaccines for RVF [23,26,41–43]; thus, it is important that reliable
animal models using a variety of challenge viruses are available for vaccine evaluation in all target
species. For example, previous RVFV challenge models have used the 1977 strain from Egypt, ZH501,
in goats and sheep [29]. While this model does provide a viremia and fever response in sheep sufficient
to evaluate vaccines [30], it does not produce clinical disease. In a previous study using two more
recently-isolated, genetically-distinct strains of RVFV (SA01 and Ken06) and sheep (Dorper/Katahdin
cross and Polypay), we observed clinical disease [31]. In this sheep study, we also found that the Ken06
produced greater liver pathology based on blood chemistry markers and histopathology. This finding
was surprising because preliminary studies that compared ZH501 with another RVFV isolate from
Kenya did not demonstrate any differences in calf responses to infection (Weingartl et al., unpublished
data). Therefore, the current study was performed to confirm and determine if the differences in
clinical signs after infection with genetically-distinct RVFV strains noted in sheep would also be found
in cattle.
In the previous sheep studies, the febrile response was found to be consistent across all
RVFV-infected animals. In this calf study, the febrile response was less consistent with both isolates.
Only two out of five SA01-inoculated calves developed a mild fever and only for one day. In the
Ken06 group, four out of five had a fever for one day, and one animal was febrile for three days
(Table 2). In most cases, the fever occurred at 2 dpi when viremia was beginning to peak. Viral RNA
was detectable in the liver and spleen for both virus groups at 3 dpi and in the brain and kidneys
of Ken06 group animals at 3 and 4 dpi. The spleens of both virus groups had detectable viral RNA
starting at 3 dpi up to 21 dpi. Virus was detected at low titer in SA01 animals in the liver and kidney
at 3 and 5 dpi, respectively. Virus was isolated with titers from 103–106 pfu/mL from the liver and
spleen at 3 and 4 dpi and from the kidney at 4 dpi for the Ken06 animals. Although viral RNA was
detected in all four tissues examined (brain, kidney, liver and spleen), the liver and spleen were the
most consistently positive by both RT-PCR and virus isolation. The presence of viral RNA in the spleen
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post-viremia potentially out to 20 dpi suggests this may be a good target tissue for diagnosis. There
was considerably more variation in the calf responses (Figure 2) than seen in the sheep study [31]. This
may have been in part because of the use of mixed breed calves due to their availability at the time of
the study. No breed susceptibility conclusions can be drawn due to the small number of animals used.
Nasal swabs from a few animals of both groups were sporadically positive for viral RNA.
Ken06 Animal #38 with the highest viremia was the only animal that also had a virus-positive nasal
swab (32 pfu/mL). Mock-inoculated control calves co-housed with the challenged animals remained
negative for all RVFV-specific parameters throughout the study, suggesting that RVFV was not shed
at levels necessary for transmission among cattle. This is consistent with the view that RVFV is most
often transmitted through an infected mosquito bite. However, although the potential for transmission
through nasal discharge is low, it should not be entirely ruled out.
The blood chemistry analysis indicated primarily liver involvement in most affected animals. As
with the previous study in sheep [31], AST appears to be the most consistent marker of clinical disease.
The small number of animals in the present study and the removal of animals for necropsy at 3, 4
and 5 dpi during the peak of viremia could have affected these results; however, the liver function
results are consistent with a previous experimental infection of calves using seven- and 21-day-old
animals [44]. Because the renal function marker BUN was also elevated in the most severely affected
animal, kidney function may also be worth monitoring in future studies.
Regardless of virus strain, at the acute time-point (3–5 dpi) post-infection, calf livers had grossly
visible multifocal necrosis that in the most severe case, Animal #38, was accompanied by marked
hemorrhage (Figures 4 and 5). These lesions contained RVFV antigen-positive cells. Differences in
hepatic histopathology due to virus strain were not noted. This could be due to the study design of
one animal per virus, per time-point. However, similar to what was seen in our sheep study [31], the
comparison of hepatic lesions from acute time-point animals for both viruses revealed that Ken06
lesions on average labeled more strongly positive for RVFV antigen (Figure 5). Lesions found in this
study were consistent with those reported in previous cattle studies [28,44,45].
Most recent studies of RVFV pathogenesis and vaccine evaluation focus on more susceptible
target species, such as sheep. This is the first study to examine virus replication and pathological
development of two distinct RVFV strains during the clinical stage of infection in cattle. Although
the fever and viremia were less consistent in cattle than sheep, the vaccine-age calf model did display
sufficient clinical responses to be useful for efficacy evaluation of cattle vaccines against RVF.
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